Article(id=1330228326096023726, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.08.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1651680000000, receivedDateStr=2022-05-05, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080747387, onlineDateStr=2026-11-19, pubDate=1660060800000, pubDateStr=2022-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080747387, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080747387, creator=13701087609, updateTime=1795080747387, updator=13701087609, issue=Issue{id=1330228319234142315, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='8', pageStart='961', pageEnd='1066', issueExtLink='null', onlineDate='null', pubDate='1660060800000', pubDateStr='2022-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080745752, creator='13701087609', updateTime=1795084770606, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245201056084694, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245201056084695, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330228319234142315, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=967, endPage=974, ext={EN=ArticleExt(id=1330228326318321839, articleId=1330228326096023726, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in the treatment of high-risk and recurrent or refractory neuroblastoma with disialoganglioside monoclonal antibody, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

The prognosis of pediatric neuroblastoma (NB) is highly heterogeneous, the long-term survival rate of high-risk or recurrent or refractory NB patients remains less than 50%. Disialoganglioside (GD2) is highly expressed in NB cells, but limited expression in normal tissues. Therefore, GD2 monoclonal antibody (mAb) therapy has become a specific immunotherapy for high-risk and recurrent or refractory NB patients. GD2 mAb binds to GD2 antigen to form immune complex, which plays antitumor effects by inducing antibody-dependent and complement-dependent immune mechanisms. GD2 mAb can significantly improve the survival rate of high-risk and recurrent or refractory NB patients, but attention should be paid to the management of adverse reactions in different groups during treatment. The timing of GD2 mAb combined with chemotherapy, as well as the benefits and risks combined with immune checkpoint inhibitors programmed cell death protein-1/programmed cell death 1 ligand-1, iodine-131-labeled metaiiodo-benzylguanidine or chimeric antigen receptor T cells should be explored. This article reviewed the research progress of GD2 mAb in the treatment of high-risk or recurrent or refractory NB in children in recent years, in order to provide some reference for clinical treatment.

, authors=Xiaojun YUAN, authorsList=Xiaojun YUAN, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330228328138649776, articleId=1330228326096023726, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=双唾液酸神经节苷脂单克隆抗体治疗儿童高危和复发/难治性神经母细胞瘤研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

儿童神经母细胞瘤(neuroblastoma,NB)预后异质性极强,高危或复发/难治性NB患者长期生存率不足50%。双唾液酸神经节苷脂抗原(disialoganglioside,GD2)在NB细胞中高表达,但在正常组织中呈限制性表达,因此GD2的单克隆抗体(monoclonal antibody,mAb)疗法已成为高危和复发/难治性NB的特异性靶向治疗方案。GD2 mAb与GD2抗原结合形成抗原-抗体免疫复合物后,通过诱导抗体依赖和补体依赖的双重免疫机制而发挥抗肿瘤作用。GD2 mAb疗法可有效提高高危和复发/难治性NB患者生存率,但应关注不同群体疗程中的不良反应管理,同时积极探索GD2 mAb与化疗联合使用的时机,及与免疫检查点抑制剂程序性死亡受体1/程序性死亡-配体1、131I-间碘苯甲基胍或嵌合抗原受体T细胞联合应用的获益与风险等。现就近年来GD2 mAb治疗儿童高危和复发/难治性NB研究进展作一综述,旨在为临床治疗提供一定参考。

, authors=袁晓军, authorsList=袁晓军, authorCompany=null, correspAuthors=null, authorNote=

袁晓军,主任医师,研究方向:儿童实体肿瘤及血液系统疾病临床诊治和基础研究。

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=2GdUPY39vnJFsiZ7AKp5qg==, magXml=HohJIW3Mg1BvFI7YWATF9w==, pdfUrl=null, pdf=BEFwFL/j2yh3rskZTm4VtQ==, pdfFileSize=1735249, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=I9x97qjwOWEXA1fXah72SQ==, mapNumber=null, fund=null)}, authors=[Author(id=1330228328461611189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228328553885879, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, authorId=1330228328461611189, language=EN, stringName=Xiaojun YUAN, firstName=Xiaojun, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228328620994744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, authorId=1330228328461611189, language=CN, stringName=袁晓军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属新华医院儿血液肿瘤科,上海 200092, bio={"content":"

袁晓军,主任医师,研究方向:儿童实体肿瘤及血液系统疾病临床诊治和基础研究。

"}, bioImg=null, bioContent=

袁晓军,主任医师,研究方向:儿童实体肿瘤及血液系统疾病临床诊治和基础研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228328365142193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, xref=null, ext=[AuthorCompanyExt(id=1330228328373530802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, companyId=1330228328365142193, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China), AuthorCompanyExt(id=1330228328381919411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, companyId=1330228328365142193, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属新华医院儿血液肿瘤科,上海 200092)])])], keywords=[Keyword(id=1330228328709075129, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=EN, orderNo=1, keyword=disialoganglioside monoclonal antibody), Keyword(id=1330228328780378298, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=EN, orderNo=2, keyword=high-risk), Keyword(id=1330228328847487163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=EN, orderNo=3, keyword=recurrent), Keyword(id=1330228328922984636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=EN, orderNo=4, keyword=refractory), Keyword(id=1330228328990093501, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=EN, orderNo=5, keyword=neuroblastoma), Keyword(id=1330228329053008062, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=EN, orderNo=6, keyword=immunotherapy), Keyword(id=1330228329132699839, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=CN, orderNo=1, keyword=双唾液酸神经节苷脂单克隆抗体), Keyword(id=1330228329191420096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=CN, orderNo=2, keyword=高危), Keyword(id=1330228329262723265, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=CN, orderNo=3, keyword=复发), Keyword(id=1330228329321443522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=CN, orderNo=4, keyword=难治), Keyword(id=1330228329380163779, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=CN, orderNo=5, keyword=神经母细胞瘤), Keyword(id=1330228329451466948, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, language=CN, orderNo=6, keyword=免疫疗法)], refs=[Reference(id=1330228329552130245, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma[J]. Cell Tissue Res, 2018, 372(2): 211-221., articleTitle=null, refAbstract=null), Reference(id=1330228329615044806, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma[J]. Lancet, 2007, 369(9579): 2106-2120., articleTitle=null, refAbstract=null), Reference(id=1330228329673765063, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Gurney JG, Ross JA, Wall DA, et al. Infant cancer in the U. S.: histology-specific incidence and trends, 1973 to 1992[J]. J Pediatr Hematol Oncol, 1997, 19(5): 428-432., articleTitle=null, refAbstract=null), Reference(id=1330228329732485320, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Uemura S, Ishida T, Thwin KKM, et al. Dynamics of minimal residual disease in neuroblastoma patients[J]. Front Oncol, 2019, 9: 455., articleTitle=null, refAbstract=null), Reference(id=1330228329803788489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Swift CC, Eklund MJ, Kraveka JM, et al. Updates in diagnosis, management, and treatment of neuroblastoma[J]. Radiographics, 2018, 38(2): 566-580., articleTitle=null, refAbstract=null), Reference(id=1330228329862508746, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy[J]. Nat Rev Cancer, 2013, 13(6): 397-411., articleTitle=null, refAbstract=null), Reference(id=1330228329946394827, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Tas ML, Reedijk AMJ, Karim-Kos HE, et al. Neuroblastoma between 1990 and 2014 in the Netherlands: increased incidence and improved survival of high-risk neuroblastoma[J]. Eur J Cancer, 2020, 124: 47-55., articleTitle=null, refAbstract=null), Reference(id=1330228330017697996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Shohet J, Foster J. Neuroblastoma[J]. BMJ, 2017, 357: j1863., articleTitle=null, refAbstract=null), Reference(id=1330228330084806861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Zage PE. Novel therapies for relapsed and refractory neuroblastoma[J]. Children (Basel), 2018, 5(11): 148., articleTitle=null, refAbstract=null), Reference(id=1330228330168692942, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk group (INRG) biology committee[J]. Br J Cancer, 2009, 100(9): 1471-1482., articleTitle=null, refAbstract=null), Reference(id=1330228330248384719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Mina M, Boldrini R, Citti A, et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma[J]. Oncoimmunology, 2015, 4(9): e1019981., articleTitle=null, refAbstract=null), Reference(id=1330228330323882192, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Pelizzo G, Veschi V, Mantelli M, et al. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells[J]. BMC Cancer, 2018, 18(1): 1176., articleTitle=null, refAbstract=null), Reference(id=1330228330386796753, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Raffaghello L, Prigione I, Airoldi I, et al. Mechanisms of immune evasion of human neuroblastoma[J]. Cancer Lett, 2005, 228(1-2): 155-161., articleTitle=null, refAbstract=null), Reference(id=1330228330458099922, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Perdicchio M, Ilarregui JM, Verstege MI, et al. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells[J]. Proc Natl Acad Sci USA, 2016, 113(12): 3329-3334., articleTitle=null, refAbstract=null), Reference(id=1330228330516820179, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Nallasamy P, Chava S, Verma SS, et al. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: immuno-oncology perspective[J]. Semin Cancer Biol, 2018, 52(2): 53-65., articleTitle=null, refAbstract=null), Reference(id=1330228330583929044, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy[J]. FEBS Lett, 2014, 588(2): 288-297., articleTitle=null, refAbstract=null), Reference(id=1330228330672009429, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Kholodenko IV, Kalinovsky DV, Doronin II, et al. Neuroblastoma origin and therapeutic targets for immunotherapy[J]. J Immunol Res, 2018, 2018: 7394268., articleTitle=null, refAbstract=null), Reference(id=1330228330760089814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Julien S, Bobowski M, Steenackers A, et al. How do gangliosides regulate RTKs signaling?[J]. Cells, 2013, 2(4): 751-767., articleTitle=null, refAbstract=null), Reference(id=1330228332374896855, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen YX, Chen XW, Li CG, et al. Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen[J]. Oncol Rep, 2013, 29(1): 343-348., articleTitle=null, refAbstract=null), Reference(id=1330228332479754456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Park JA, Cheung NV. Targets and antibody formats for immunotherapy of neuroblastoma[J]. J Clin Oncol, 2020, 38(16): 1836-1848., articleTitle=null, refAbstract=null), Reference(id=1330228332567834841, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Voeller J, Sondel PM. Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma[J]. J Pediatr Hematol Oncol, 2019, 41(3): 163-169., articleTitle=null, refAbstract=null), Reference(id=1330228332634943706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody[J]. J Immunol, 1990, 144(4): 1382-1386., articleTitle=null, refAbstract=null), Reference(id=1330228332743995611, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Ladenstein R, Weixler S, Baykan B, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: a SIOPEN phase 1 study[J]. MAbs, 2013, 5(5): 801-809., articleTitle=null, refAbstract=null), Reference(id=1330228332915962076, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Sorkin LS, Otto M, Baldwin WM 3rd, et al. Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia[J]. Pain, 2010, 149(1): 135-142., articleTitle=null, refAbstract=null), Reference(id=1330228332995653853, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy[J]. Biologics, 2019, 13: 1-12, articleTitle=null, refAbstract=null), Reference(id=1330228333125677278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=GD2单抗治疗神经母细胞瘤临床应用协作组. GD2抗体达妥昔单抗β治疗神经母细胞瘤的临床应用专家共识(2021年版)[J]. 临床儿科杂志, 2022, 40(1): 14-20., articleTitle=null, refAbstract=null), Reference(id=1330228333188591839, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Full prescribing information: contents (unituxin)[EB/OL]. (2022-03-05). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125516s025lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228333259895008, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Full prescribing information: contents (danyelza)[EB/OL]. (2022-03-05). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228333335392481, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334., articleTitle=null, refAbstract=null), Reference(id=1330228333410889954, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Dhillon S. Dinutuximab: first global approval[J]. Drugs, 2015, 75(8): 923-927., articleTitle=null, refAbstract=null), Reference(id=1330228333486387427, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Yu AL, Gilman AL, Ozkaynak MF, et al. Long-term follow-up of a phase Ⅲ study of ch14.18 (dinutuximab)+cytokine immunotherapy in children with high-risk neuroblastoma: COG study AN-BL0032[J]. Clin Cancer Res, 2021, 27(8): 2179-2189., articleTitle=null, refAbstract=null), Reference(id=1330228333549301988, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Ladenstein R, Pötschger U, Valteau-Couanet D, et al. investigation of the role of dinutuximab β-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1)[J]. Cancers (Basel), 2020, 12(2): 309., articleTitle=null, refAbstract=null), Reference(id=1330228333612216549, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Ladenstein R, Potschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab β) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12): 1617-1629., articleTitle=null, refAbstract=null), Reference(id=1330228333675131110, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=袁晓军, 钱晓文, 李杰, 等. GD2单抗治疗中国高危及复发难治神经母细胞瘤儿童的临床研究初探[J]. 中华转移性肿瘤杂志, 2022, 5(1): 14-20., articleTitle=null, refAbstract=null), Reference(id=1330228333754822887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Mora J, Castaneda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission[J]. Pediatr Blood Cancer, 2021, 68(10): e29121., articleTitle=null, refAbstract=null), Reference(id=1330228333821931752, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Mastrangelo S, Rivetti S, Triarico S, et al. Mechanisms, characteristics, and treatment of neuropathic pain and peripheral neuropathy associated with dinutuximab in neuroblastoma patients[J]. Int J Mol Sci, 2021, 22(23): 12648., articleTitle=null, refAbstract=null), Reference(id=1330228333880652009, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO[J]. MAbs, 2018, 10(1): 55-61., articleTitle=null, refAbstract=null), Reference(id=1330228333935177962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Bertolizio G, Otis A, Tam K, et al. Multimodal analgesic plan for children undergoing chimeric 14.18 immunotherapy[J]. J Pediatr Hematol Oncol, 2021, 43(2): e169-e172., articleTitle=null, refAbstract=null), Reference(id=1330228333998092523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Castañeda A, Gorostegui M, Miralles SL, et al. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the hospital Sant Joan De Déu in Barcelona, Spain[J]. ESMO Open, 2022, 7(2): 100462., articleTitle=null, refAbstract=null), Reference(id=1330228334056812780, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=European Medicines Agency. Qarziba (previously dinutuximab β EUSA and dinutuximab β apeiron)[EB/OL]. [2021-12-07]. (2022-03-05). https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-productinformation_en-0.pdf., articleTitle=null, refAbstract=null), Reference(id=1330228334115533037, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Kremens B, Hero B, Esser J, et al. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma[J]. Cancer Immunol Immunother, 2002, 51(2): 107-110., articleTitle=null, refAbstract=null), Reference(id=1330228334178447598, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Tse BC, Navid F, Billups CA, et al. Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A[J]. J AAPOS, 2015, 19(2): 112-115., articleTitle=null, refAbstract=null), Reference(id=1330228334245556463, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Blom T, Lurvink R, Aleven L, et al. Treatment-related toxicities during anti-GD2 immunotherapy in high-risk neuroblastoma patients[J]. Front Oncol, 2020, 10: 601076., articleTitle=null, refAbstract=null), Reference(id=1330228334321053936, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Mody R, Naranjo A, Van Ryn C, et al. Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2017, 18(7): 946-957., articleTitle=null, refAbstract=null), Reference(id=1330228334404940018, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma[J]. J Neurooncol, 2010, 97(3): 409-418., articleTitle=null, refAbstract=null), Reference(id=1330228334467854579, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Furman WL, Federico SM, Mccarville MB, et al. A phase Ⅱ trial of hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma[J]. Clin Cancer Res, 2019, 25(21): 6320-6328., articleTitle=null, refAbstract=null), Reference(id=1330228334526574836, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Caforio M, Sorino C, Caruana I, et al. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFN-γ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape[J]. J Immunother Cancer, 2021, 9(3): e001502., articleTitle=null, refAbstract=null), Reference(id=1330228334593683701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Ehlert K, Hansjuergens I, Zinke A, et al. Nivolumab and dinutuximab β in two patients with refractory neuroblastoma[J]. J Immunother Cancer, 2020, 8(1): e000540., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1330228328365142193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, xref=null, ext=[AuthorCompanyExt(id=1330228328373530802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, companyId=1330228328365142193, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China), AuthorCompanyExt(id=1330228328381919411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, companyId=1330228328365142193, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属新华医院儿血液肿瘤科,上海 200092)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.08.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.08.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.08.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.08.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1660060800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
双唾液酸神经节苷脂单克隆抗体治疗儿童高危和复发/难治性神经母细胞瘤研究进展
袁晓军
世界临床药物 | 医药专论 2022,43(8): 967-974
收起
收藏切换
世界临床药物 |医药专论 2022 , 43 (8) : 967 -974
双唾液酸神经节苷脂单克隆抗体治疗儿童高危和复发/难治性神经母细胞瘤研究进展
全屏
[Author(id=1330228328461611189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330228328553885879, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, authorId=1330228328461611189, language=EN, stringName=Xiaojun YUAN, firstName=Xiaojun, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330228328620994744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, authorId=1330228328461611189, language=CN, stringName=袁晓军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属新华医院儿血液肿瘤科,上海 200092, bio={"content":"

袁晓军,主任医师,研究方向:儿童实体肿瘤及血液系统疾病临床诊治和基础研究。

"}, bioImg=null, bioContent=

袁晓军,主任医师,研究方向:儿童实体肿瘤及血液系统疾病临床诊治和基础研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330228328365142193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, xref=null, ext=[AuthorCompanyExt(id=1330228328373530802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, companyId=1330228328365142193, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China), AuthorCompanyExt(id=1330228328381919411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330228326096023726, companyId=1330228328365142193, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属新华医院儿血液肿瘤科,上海 200092)])])]
袁晓军
作者信息
  • 上海交通大学医学院附属新华医院儿血液肿瘤科,上海 200092
作者简介:

袁晓军,主任医师,研究方向:儿童实体肿瘤及血液系统疾病临床诊治和基础研究。

Advances in the treatment of high-risk and recurrent or refractory neuroblastoma with disialoganglioside monoclonal antibody
Xiaojun YUAN
Affiliations
  • Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
出版时间: 2022-08-10 doi: 10.13683/j.wph.2022.08.002
文章导航
收藏切换

儿童神经母细胞瘤(neuroblastoma,NB)预后异质性极强,高危或复发/难治性NB患者长期生存率不足50%。双唾液酸神经节苷脂抗原(disialoganglioside,GD2)在NB细胞中高表达,但在正常组织中呈限制性表达,因此GD2的单克隆抗体(monoclonal antibody,mAb)疗法已成为高危和复发/难治性NB的特异性靶向治疗方案。GD2 mAb与GD2抗原结合形成抗原-抗体免疫复合物后,通过诱导抗体依赖和补体依赖的双重免疫机制而发挥抗肿瘤作用。GD2 mAb疗法可有效提高高危和复发/难治性NB患者生存率,但应关注不同群体疗程中的不良反应管理,同时积极探索GD2 mAb与化疗联合使用的时机,及与免疫检查点抑制剂程序性死亡受体1/程序性死亡-配体1、131I-间碘苯甲基胍或嵌合抗原受体T细胞联合应用的获益与风险等。现就近年来GD2 mAb治疗儿童高危和复发/难治性NB研究进展作一综述,旨在为临床治疗提供一定参考。

双唾液酸神经节苷脂单克隆抗体  /  高危  /  复发  /  难治  /  神经母细胞瘤  /  免疫疗法

The prognosis of pediatric neuroblastoma (NB) is highly heterogeneous, the long-term survival rate of high-risk or recurrent or refractory NB patients remains less than 50%. Disialoganglioside (GD2) is highly expressed in NB cells, but limited expression in normal tissues. Therefore, GD2 monoclonal antibody (mAb) therapy has become a specific immunotherapy for high-risk and recurrent or refractory NB patients. GD2 mAb binds to GD2 antigen to form immune complex, which plays antitumor effects by inducing antibody-dependent and complement-dependent immune mechanisms. GD2 mAb can significantly improve the survival rate of high-risk and recurrent or refractory NB patients, but attention should be paid to the management of adverse reactions in different groups during treatment. The timing of GD2 mAb combined with chemotherapy, as well as the benefits and risks combined with immune checkpoint inhibitors programmed cell death protein-1/programmed cell death 1 ligand-1, iodine-131-labeled metaiiodo-benzylguanidine or chimeric antigen receptor T cells should be explored. This article reviewed the research progress of GD2 mAb in the treatment of high-risk or recurrent or refractory NB in children in recent years, in order to provide some reference for clinical treatment.

disialoganglioside monoclonal antibody  /  high-risk  /  recurrent  /  refractory  /  neuroblastoma  /  immunotherapy
袁晓军. 双唾液酸神经节苷脂单克隆抗体治疗儿童高危和复发/难治性神经母细胞瘤研究进展. 世界临床药物, 2022 , 43 (8) : 967 -974 . DOI: 10.13683/j.wph.2022.08.002
Xiaojun YUAN. Advances in the treatment of high-risk and recurrent or refractory neuroblastoma with disialoganglioside monoclonal antibody[J]. World Clinical Drug, 2022 , 43 (8) : 967 -974 . DOI: 10.13683/j.wph.2022.08.002

参考文献 引证文献
排序方式:
[1]
Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma[J]. Cell Tissue Res, 2018, 372(2): 211-221.
[2]
Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma[J]. Lancet, 2007, 369(9579): 2106-2120.
[3]
Gurney JG, Ross JA, Wall DA, et al. Infant cancer in the U. S.: histology-specific incidence and trends, 1973 to 1992[J]. J Pediatr Hematol Oncol, 1997, 19(5): 428-432.
[4]
Uemura S, Ishida T, Thwin KKM, et al. Dynamics of minimal residual disease in neuroblastoma patients[J]. Front Oncol, 2019, 9: 455.
[5]
Swift CC, Eklund MJ, Kraveka JM, et al. Updates in diagnosis, management, and treatment of neuroblastoma[J]. Radiographics, 2018, 38(2): 566-580.
[6]
Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy[J]. Nat Rev Cancer, 2013, 13(6): 397-411.
[7]
Tas ML, Reedijk AMJ, Karim-Kos HE, et al. Neuroblastoma between 1990 and 2014 in the Netherlands: increased incidence and improved survival of high-risk neuroblastoma[J]. Eur J Cancer, 2020, 124: 47-55.
[8]
Shohet J, Foster J. Neuroblastoma[J]. BMJ, 2017, 357: j1863.
[9]
Zage PE. Novel therapies for relapsed and refractory neuroblastoma[J]. Children (Basel), 2018, 5(11): 148.
[10]
Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk group (INRG) biology committee[J]. Br J Cancer, 2009, 100(9): 1471-1482.
[11]
Mina M, Boldrini R, Citti A, et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma[J]. Oncoimmunology, 2015, 4(9): e1019981.
[12]
Pelizzo G, Veschi V, Mantelli M, et al. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells[J]. BMC Cancer, 2018, 18(1): 1176.
[13]
Raffaghello L, Prigione I, Airoldi I, et al. Mechanisms of immune evasion of human neuroblastoma[J]. Cancer Lett, 2005, 228(1-2): 155-161.
[14]
Perdicchio M, Ilarregui JM, Verstege MI, et al. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells[J]. Proc Natl Acad Sci USA, 2016, 113(12): 3329-3334.
[15]
Nallasamy P, Chava S, Verma SS, et al. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: immuno-oncology perspective[J]. Semin Cancer Biol, 2018, 52(2): 53-65.
[16]
Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy[J]. FEBS Lett, 2014, 588(2): 288-297.
[17]
Kholodenko IV, Kalinovsky DV, Doronin II, et al. Neuroblastoma origin and therapeutic targets for immunotherapy[J]. J Immunol Res, 2018, 2018: 7394268.
[18]
Julien S, Bobowski M, Steenackers A, et al. How do gangliosides regulate RTKs signaling?[J]. Cells, 2013, 2(4): 751-767.
[19]
Chen YX, Chen XW, Li CG, et al. Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen[J]. Oncol Rep, 2013, 29(1): 343-348.
[20]
Park JA, Cheung NV. Targets and antibody formats for immunotherapy of neuroblastoma[J]. J Clin Oncol, 2020, 38(16): 1836-1848.
[21]
Voeller J, Sondel PM. Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma[J]. J Pediatr Hematol Oncol, 2019, 41(3): 163-169.
[22]
Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody[J]. J Immunol, 1990, 144(4): 1382-1386.
[23]
Ladenstein R, Weixler S, Baykan B, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: a SIOPEN phase 1 study[J]. MAbs, 2013, 5(5): 801-809.
[24]
Sorkin LS, Otto M, Baldwin WM 3rd, et al. Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia[J]. Pain, 2010, 149(1): 135-142.
[25]
Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy[J]. Biologics, 2019, 13: 1-12
[26]
GD2单抗治疗神经母细胞瘤临床应用协作组. GD2抗体达妥昔单抗β治疗神经母细胞瘤的临床应用专家共识(2021年版)[J]. 临床儿科杂志, 2022, 40(1): 14-20.
[27]
Full prescribing information: contents (unituxin)[EB/OL]. (2022-03-05). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125516s025lbl.pdf.
[28]
Full prescribing information: contents (danyelza)[EB/OL]. (2022-03-05). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf.
[29]
Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334.
[30]
Dhillon S. Dinutuximab: first global approval[J]. Drugs, 2015, 75(8): 923-927.
[31]
Yu AL, Gilman AL, Ozkaynak MF, et al. Long-term follow-up of a phase Ⅲ study of ch14.18 (dinutuximab)+cytokine immunotherapy in children with high-risk neuroblastoma: COG study AN-BL0032[J]. Clin Cancer Res, 2021, 27(8): 2179-2189.
[32]
Ladenstein R, Pötschger U, Valteau-Couanet D, et al. investigation of the role of dinutuximab β-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1)[J]. Cancers (Basel), 2020, 12(2): 309.
[33]
Ladenstein R, Potschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab β) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12): 1617-1629.
[34]
袁晓军, 钱晓文, 李杰, 等. GD2单抗治疗中国高危及复发难治神经母细胞瘤儿童的临床研究初探[J]. 中华转移性肿瘤杂志, 2022, 5(1): 14-20.
[35]
Mora J, Castaneda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission[J]. Pediatr Blood Cancer, 2021, 68(10): e29121.
[36]
Mastrangelo S, Rivetti S, Triarico S, et al. Mechanisms, characteristics, and treatment of neuropathic pain and peripheral neuropathy associated with dinutuximab in neuroblastoma patients[J]. Int J Mol Sci, 2021, 22(23): 12648.
[37]
Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO[J]. MAbs, 2018, 10(1): 55-61.
[38]
Bertolizio G, Otis A, Tam K, et al. Multimodal analgesic plan for children undergoing chimeric 14.18 immunotherapy[J]. J Pediatr Hematol Oncol, 2021, 43(2): e169-e172.
[39]
Castañeda A, Gorostegui M, Miralles SL, et al. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the hospital Sant Joan De Déu in Barcelona, Spain[J]. ESMO Open, 2022, 7(2): 100462.
[40]
European Medicines Agency. Qarziba (previously dinutuximab β EUSA and dinutuximab β apeiron)[EB/OL]. [2021-12-07]. (2022-03-05). https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-productinformation_en-0.pdf.
[41]
Kremens B, Hero B, Esser J, et al. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma[J]. Cancer Immunol Immunother, 2002, 51(2): 107-110.
[42]
Tse BC, Navid F, Billups CA, et al. Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A[J]. J AAPOS, 2015, 19(2): 112-115.
[43]
Blom T, Lurvink R, Aleven L, et al. Treatment-related toxicities during anti-GD2 immunotherapy in high-risk neuroblastoma patients[J]. Front Oncol, 2020, 10: 601076.
[44]
Mody R, Naranjo A, Van Ryn C, et al. Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2017, 18(7): 946-957.
[45]
Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma[J]. J Neurooncol, 2010, 97(3): 409-418.
[46]
Furman WL, Federico SM, Mccarville MB, et al. A phase Ⅱ trial of hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma[J]. Clin Cancer Res, 2019, 25(21): 6320-6328.
[47]
Caforio M, Sorino C, Caruana I, et al. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFN-γ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape[J]. J Immunother Cancer, 2021, 9(3): e001502.
[48]
Ehlert K, Hansjuergens I, Zinke A, et al. Nivolumab and dinutuximab β in two patients with refractory neuroblastoma[J]. J Immunother Cancer, 2020, 8(1): e000540.
2022年第43卷第8期
14
4
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.08.002
  • 接收时间:2022-05-05
  • 首发时间:2026-11-19
  • 出版时间:2022-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-05-05
基金
作者信息
    上海交通大学医学院附属新华医院儿血液肿瘤科,上海 200092
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.08.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏